May 14, 2021

Antibody Responses to Single-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunomodulators for Immune-Mediated Inflammatory Disease

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): vaccine

• A study of persons with immune-mediated inflammatory diseases (IMID) (N=120) found that 15% failed to produce detectable SARS-CoV-2 antibodies 23-46 days after one dose of the Pfizer-BioNTech or Astra-Zeneca vaccines. In contrast, nearly 100% of persons without IMID who receive one dose of either vaccine have been shown to produce antibodies within this time frame. Persons taking immunomodulating medications had a non-significantly lower odds of detectable antibody response (OR=0.31). All persons with previous confirmed SARS-CoV-2 infection produced antibodies. The authors suggest that further studies are needed to examine antibody titers in the population following two doses and to establish titer levels that correspond to protection against COVID-19. 

Al-Janabi et al. (May 2021). Antibody Responses to Single-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunomodulators for Immune-Mediated Inflammatory Disease. The British Journal of Dermatology. https://doi.org/10.1111/bjd.20479